

Epidemiological Evidence of Drug Metabolism Gene Polymorphisms and Individual Differences in Drug Response

Enqi Zhang *

Department of Pharmacy, Shanghai Jiao Tong University, Shanghai, 200240, China

* Corresponding Author Email: zhangenqi@sjtu.edu.cn

Abstract. Interindividual variability in drug response poses a significant challenge in clinical practice, leading to treatment failure or adverse drug reactions (ADRs). A substantial portion of this variability is driven by genetic polymorphisms in key pharmacogenes. This review aims to synthesize the robust evidence and clinical guidelines for major gene-drug pairs and to discuss the critical evidence gaps hindering the equitable global implementation of pharmacogenomics. We conducted a comprehensive review of systematic reviews, meta-analyses, and clinical guidelines from consortia like the Clinical Pharmacogenetics Implementation Consortium (CPIC) for key gene-drug interactions, including CYP2C19-clopidogrel, CYP2C9/VKORC1-warfarin, SLCO1B1-statins, and SLC22A1-metformin. Furthermore, we examined the issue of population bias in genetic research and the need for real-world evidence. Strong evidence confirms that genetic variants significantly alter the efficacy and toxicity of numerous drugs. CPIC guidelines provide actionable recommendations for genotype-guided therapy, such as alternative antiplatelet agents for CYP2C19 poor metabolizers and dose adjustments for warfarin and statins.

Keywords: Pharmacogenomics, Interindividual Variability, Clinical Guidelines, Health Disparities, Real-world Evidence.

1. Introduction

Individual variability in drug response represents a major challenge in clinical practice, leading to either subtherapeutic efficacy or increased adverse drug reactions (ADRs). Such variability is often attributable to genetic polymorphisms in key drug-metabolizing enzymes and transporters, including CYP2C19, CYP2D6, CYP2C9, VKORC1, SLCO1B1, and SLC22A1 [1]. These genetic variations influence drug pharmacokinetics and pharmacodynamics, thereby modulating therapeutic outcomes across diverse populations [2].

The foundational principle of modern pharmacotherapy is increasingly challenged by the pervasive observation of interindividual variability in drug response, a critical issue that manifests as therapeutic failure in some patients and severe adverse drug reactions (ADRs) in others [3]. This variability not only leads to suboptimal patient outcomes but also constitutes a significant and growing economic burden on healthcare systems globally, due to increased hospitalizations, additional treatments, and lost productivity. It is now unequivocally established that a substantial portion of this heterogeneity is attributable to genetic polymorphisms in genes encoding drug-metabolizing enzymes, transporters, and targets. Key pharmacogenes such as CYP2C19, CYP2D6, CYP2C9, VKORC1, SLCO1B1, and SLC22A1 [4] play a pivotal role in determining the pharmacokinetics and pharmacodynamics of a wide array of commonly prescribed medications, thereby acting as a major driver of individual differences in drug efficacy and toxicity profiles [5].

The field of pharmacogenomics has progressed significantly from discovery to implementation, with robust evidence now supporting the clinical utility of testing for specific gene-drug pairs. For instance, carriage of loss-of-function alleles in CYP2C19 (e.g., *2, *3) is strongly associated with impaired activation of the antiplatelet prodrug clopidogrel, leading to a significantly higher risk of major adverse cardiovascular events (MACE), such as stent thrombosis, in patients undergoing percutaneous coronary intervention [6]. Similarly, genetic variants in VKORC1 and CYP2C9 are the foremost determinants of warfarin dosing requirements and susceptibility to bleeding complications, with dosing algorithms incorporating these genotypes outperforming clinical algorithms alone [7].

Beyond metabolism, transporter genomics is equally critical; the rs4149056 (c.521T>C) variant in SLCO1B1, which encodes the organic anion-transporting polypeptide 1B1 responsible for the hepatic uptake of statins, is a well-validated genetic marker for simvastatin-induced myopathy [8]. Furthermore, variations in SLC22A1 (OCT1), which influence the hepatic uptake of metformin, contribute to the variability in the glycemic response to this first-line antidiabetic agent [9]. This accumulating evidence has been systematically translated into actionable clinical guidelines by international consortia like the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG), facilitating the gradual integration of pharmacogenetic testing into routine clinical care to personalize drug therapy and improve patient safety.

Despite these considerable advancements, the translation of pharmacogenomics into equitable global health benefits is hampered by two persistent and critical evidence gaps. The first is the pronounced inequity in the representation of diverse populations in pharmacogenetic research. Recent analyses continue to confirm that over 80% of participants in genome-wide association studies (GWAS) are of European ancestry. This creates a severe bias, as the allele frequencies and linkage disequilibrium patterns of clinically relevant variants in genes like CYP2D6 and CYP2C19 exhibit substantial divergence across different ethnicities. For example, the CYP2D6*10 reduced function allele is common in East Asian populations (~40-50%) but rare in Europeans, while CYP2C19*17 (ultrarapid metabolizer) is more frequent in Middle Eastern populations [10]. Consequently, the effect sizes, risk predictions, and clinical thresholds derived from predominantly Eurocentric datasets may not be directly generalizable to underrepresented populations in Africa, Asia, and Latin America, risking the exacerbation of existing global health disparities if applied without validation.

The second gap lies in the need for large-scale, real-world evidence (RWE) to quantify the precise clinical impact and cost-effectiveness of pre-emptive pharmacogenetic testing. While randomized controlled trials (RCTs) provide high-quality evidence of efficacy, their controlled settings often do not fully reflect the complexity of real-world clinical practice with comorbidities and polypharmacy. Although implementation studies like the PREPARE trial have shown positive results, there remains a need for broader analyses across diverse healthcare systems to rigorously quantify the effect sizes of "gene-drug-outcome" relationships in routine care settings and to define clear, actionable thresholds for genotype-guided interventions that can inform health policy.

Therefore, the primary motivation for this study is to directly address these contemporary evidence gaps by leveraging the power of large-scale, multi-ethnic biobanks. Our research aims to utilize extensive data from the UK Biobank, the All of Us Research Program, and NHANES to provide a comprehensive and quantitative analysis of the impact of key pharmacogenetic variants on hard clinical endpoints of drug efficacy and toxicity. A specific focus will be placed on evaluating the transferability of these associations across diverse ancestral groups and on generating robust, real-world evidence to support the development of more precise, equitable, and actionable genotype-stratified drug therapy recommendations.

2. Methods

2.1. Data Sources

This NIH-led initiative aims to build a diverse health database from over one million participants in the United States. Its core strength for this study is its deliberate focus on recruiting underrepresented populations and linking whole-genome sequencing (WGS) and genotyping data to rich Electronic Health Records (EHRs), including detailed medication history. This dataset is crucial for directly assessing the cross-population transferability of pharmacogenetic associations.

While not primarily a genetic cohort, NHANES provides valuable cross-sectional data on self-reported medication use, detailed laboratory measurements (e.g., LDL cholesterol, HbA1c, serum creatinine, ALT), and limited genetic data (e.g., CYP2C9*2, *3 for warfarin response in some cycles).

It is particularly suitable for investigating intermediate metabolic phenotypes (e.g., statin-induced lipid-lowering efficacy, metformin-related changes in glucose levels) and prevalence estimates.

2.2. Study Population

For each database, we will define specific study cohorts based on drug exposure. Participants aged 18 years and older with available genetic data and documented exposure to one of the target drugs (e.g., clopidogrel, warfarin, statins, metformin).

Exclusion Criteria: Participants will be excluded for: (1) missing key covariate data (e.g., age, sex); (2) having conditions that severely alter drug pharmacokinetics/pharmacodynamics (e.g., end-stage renal disease on dialysis, severe hepatic cirrhosis); (3) extreme polypharmacy (concurrent use of >10 medications) to reduce confounding by complex drug interactions.

2.3. Variable Design

The study will extract key pharmacogenetic variants (e.g., CYP2C19, CYP2D6, CYP2C9, VKORC1, SLCO1B1, SLC22A1) and classify subjects into consensus-based metaboliser phenotypes. Drug exposure from biobank prescription records or self-reports will be modelled as time-varying covariates. Outcomes include efficacy (MACE with clopidogrel, LDL reduction with statins, INR response to warfarin) and toxicity (warfarin bleeding, statin myopathy, metformin intolerance). Covariates such as demographics, clinical risk factors, and concomitant medications will be adjusted as confounders.

2.4. Statistical Analysis

All analyses will be conducted separately for each drug-outcome pair within each database. For genetic association analyses, each variant site will be tested for its relationship with the outcome using regression models adjusted for covariates. Where the outcome is a time-to-event variable (e.g., major adverse cardiovascular events or hospitalisation), Cox proportional hazards models will be employed to calculate hazard ratios (HR) and 95% confidence intervals (CI). For dichotomous outcomes (e.g., occurrence of toxic reactions), odds ratios (OR) and 95% CIs will be calculated using logistic regression; for continuous outcomes (e.g., changes in low-density lipoprotein), linear regression analysis will be employed. In the phenotypic baseline analysis, differences between distinct predicted phenotype groups (e.g., poor metabolisers versus normal metabolisers) will be compared. All primary analyses will be stratified by primary population origin (e.g., Europeans, Africans, East Asians) to assess heterogeneity in genetic effects. Where the same drug-outcome pair yielded results across multiple databases, estimates were pooled via fixed-effect or random-effects meta-analysis to enhance statistical power. To control the false discovery rate (FDR) arising from multiple testing, the Benjamini-Hochberg method was applied within each category of tests (e.g., all tests for a single drug), maintaining the FDR at 5%.

3. Results

A substantial body of evidence from clinical studies, systematic reviews, and meta-analyses has established the critical role of pharmacogenetics in explaining interindividual variability in drug response. This evidence has been systematically translated into actionable clinical guidelines by international consortia such as the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) [4].

Clopidogrel and CYP2C19: Existing studies widely report that carriers of loss-of-function (LOF) alleles in CYP2C19 (e.g., *2, *3) exhibit impaired activation of the prodrug clopidogrel, leading to reduced antiplatelet activity [11]. Multiple systematic reviews and meta-analyses have confirmed that CYP2C19 poor metabolizers (PMs) face a significantly higher risk of major adverse cardiovascular events (MACE), particularly stent thrombosis, following percutaneous coronary intervention.

Consequently, CPIC and DPWG guidelines strongly recommend alternative antiplatelet therapies (e.g., prasugrel or ticagrelor) for CYP2C19 intermediate and poor metabolizers [6].

Warfarin and CYP2C9/VKORC1: Genetic polymorphisms in VKORC1 and CYP2C9 are the foremost determinants of warfarin dosing requirements and susceptibility to bleeding complications. VKORC1 variants influence warfarin's sensitivity, while CYP2C9 variants (e.g., *2, *3) reduce its metabolic clearance [11-13]. Numerous studies and dosing algorithms have demonstrated that incorporating genetic information from these genes results in more accurate initial dosing, a faster time to achieve a stable therapeutic INR, and a reduced risk of serious bleeding events compared to clinical algorithms alone [14-16]. CPIC guidelines provide detailed, genotype-based dosing recommendations for warfarin.

Statins and SLCO1B1: The association between the SLCO1B1 rs4149056 (c.521T>C) variant and an increased risk of statin-associated musculoskeletal symptoms (SAMSS), particularly for simvastatin, is one of the most robust in pharmacogenomics [14]. This variant reduces the hepatic uptake of statins, increasing systemic exposure and the risk of toxicity [15]. Large-scale cohort studies and meta-analyses have consistently validated this association. CPIC guidelines recommend using a lower dose of simvastatin or an alternative statin (e.g., pravastatin or rosuvastatin) for carriers of the risk allele to mitigate myopathy risk [8].

Metformin and SLC22A1 (OCT1): Variations in the SLC22A1 gene, which encodes the organic cation transporter 1 (OCT1), influence the hepatic uptake and pharmacokinetics of metformin [16]. Evidence suggests that certain reduced-function alleles are associated with a diminished glycemic response, as measured by HbA1c reduction [9]. While the effect size is considered moderate and not yet sufficient to warrant routine pre-prescription genotyping, it provides a compelling biological explanation for a portion of the variability in response to this first-line antidiabetic agent. Research in this area remains active [17,18]. Further research should evaluate combined effect with gut microbiome and polygenic background

Overall Summary: The evidence for the clinical validity of these gene-drug pairs is overwhelmingly strong, particularly for CYP2C19-clopidogrel, *CYP2C9/VKORC1*-warfarin, and SLCO1B1-simvastatin. CPIC and DPWG guidelines have successfully translated this evidence into clear, graded recommendations for clinical action, facilitating the move towards personalized medicine to enhance drug efficacy and safety. Integration of these guidelines into electronic prescribing systems can reduce adverse events and improve therapeutic outcomes [19,20].

4. Summary

In conclusion, this review synthesizes the robust and well-established body of evidence linking genetic polymorphisms in key pharmacogenes to clinically significant differences in drug response. The associations between CYP2C19 and clopidogrel efficacy, *VKORC1/CYP2C9* and warfarin dosing, and SLCO1B1 and statin-induced myopathy are supported by a high level of evidence from meta-analyses and large cohort studies and have been formally endorsed by leading international consortia like CPIC and DPWG. These guidelines provide clear, actionable recommendations for genotype-guided prescribing, marking a significant advancement towards the implementation of precision medicine. However, the translation of these findings into equitable global health benefits faces a major challenge: the predominant reliance on genetic data from European-ancestry populations. The extrapolation of genetic effects and dosing algorithms across diverse ethnic groups without validation risks exacerbating existing health disparities. Without inclusion of diverse populations, pharmacogenetic-guided therapy risks reinforcing health disparities. Therefore, future efforts must prioritize the generation of real-world evidence from multi-ethnic cohorts to quantify population-specific genetic effects, refine clinical thresholds, and ensure the equitable application of pharmacogenomics. The integration of polygenic risk scores with clinical factors and the exploration of multi-omics approaches hold promise for further personalizing therapy, but their development and

validation must be inclusive from the outset to build a truly effective and fair framework for personalized drug therapy worldwide.

References

- [1] Kassogue Y, Fricke-Galindo I. Editorial: The impact of the human genome on interindividual variability in drug response. *Front Genet.* 2024 Apr 18; 15:1401604. doi: 10.3389/fgene.2024.1401604. PMID: 38711917; PMCID: PMC11070934.
- [2] Zhou Y, Arribas GH, Turku A, Jürgenson T, Mkrtchian S, Krebs K, Wang Y, Svobodova B, Milani L, Schulte G, Korabecny J, Gastaldello S, Lauschke VM. Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine. *Sci Adv.* 2021 Sep 3;7(36):eabi6856. doi: 10.1126/sciadv. abi6856. Epub 2021 Sep 1. PMID: 34516913; PMCID: PMC8442892.
- [3] Thabet RH, Alshar BOS, Alabdallah DHS, Alhmoud NAZA, Alslameen STA, Thabet YRH. Structure-activity relationships andz interindividual variability of drug responses: pharmacogenomics with antimicrobial drugs as a paradigm. *J Int Med Res.* 2023 Nov;51(11):3000605231214065. doi: 10.1177/03000605231214065. PMID: 38019107; PMCID: PMC10687969.
- [4] Bousman CA, Stevenson JM, Ramsey LB, Sangkuhl K, Hicks JK, Strawn JR, Singh AB, Ruaño G, Mueller DJ, Tsermpini EE, Brown JT, Bell GC, Leeder JS, Gaedigk A, Scott SA, Klein TE, Caudle KE, Bishop JR. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. *Clin Pharmacol Ther.* 2023 Jul;114(1):51-68. doi: 10.1002/cpt.2903. Epub 2023 May 30. PMID: 37032427; PMCID: PMC10564324.
- [5] Milosavljevic F, Bukvic N, Pavlovic Z, Miljevic C, Pešic V, Molden E, Ingelman-Sundberg M, Leucht S, Jukic MM. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis. *JAMA Psychiatry.* 2021 Mar 1;78(3):270-280. doi: 10.1001/jamapsychiatry.2020.3643. PMID: 33237321; PMCID: PMC7702196.
- [6] Bauer T, Bouman HJ, van Werkum JW, Ford NF, ten Berg JM, Taubert D. Impact of CYP2C19 variant genotypes on clinical efficacy of antiplatelet treatment with clopidogrel: systematic review and meta-analysis. *BMJ.* 2011 Aug 4;343: d4588. doi: 10.1136/bmj. d4588. PMID: 21816733; PMCID: PMC3191560.
- [7] Farajzadeh-Dehkordi M, Samiee-Rad F, Farzam SS, Javadi A, Cheraghi S, Hamed-Asl D, Rahmani B. Evaluation of a warfarin dosing algorithm including CYP2C9, VKORC1, and CYP4F2 polymorphisms and non-genetic determinants for the Iranian population. *Pharmacol Rep.* 2023 Jun;75(3):695-704. doi: 10.1007/s43440-023-00476-2. Epub 2023 Apr 11. PMID: 37039974.
- [8] Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLC01B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. *Clin Pharmacol Ther.* 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.
- [9] Ningrum VDA, Sadewa AH, Ikawati Z, Yuliwulandari R, Ikhsan MR, Fajriyah R. The influence of metformin transporter gene SLC22A1 and SLC47A1 variants on steady-state pharmacokinetics and glycemic response. *PLoS One.* 2022 Jul 29;17(7): e0271410. doi: 10.1371/journal.pone.0271410. PMID: 35905099; PMCID: PMC9337647.
- [10] Scheinfeldt LB, Brangan A, Kusic DM, Kumar S, Gharani N. Common Treatment, Common Variant: Evolutionary Prediction of Functional Pharmacogenomic Variants. *J Pers Med.* 2021 Feb 16;11(2):131. doi: 10.3390/jpm11020131. PMID: 33669176; PMCID: PMC7919641.
- [11] Lee CR, Luzum JA, Sangkuhl K, Gammal RS, Sabatine MS, Stein CM, Kisor DF, Limdi NA, Lee YM, Scott SA, Hulot JS, Roden DM, Gaedigk A, Caudle KE, Klein TE, Johnson JA, Shuldiner AR. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. *Clin Pharmacol Ther.* 2022 Nov;112(5):959-967. doi: 10.1002/cpt.2526. Epub 2022 Feb 8. PMID: 35034351; PMCID: PMC9287492.

- [12] Holail J, Mobarak R, Al-Ghamdi B, Aljada A, Fakhoury H. Association of VKORC1 and CYP2C9 single-nucleotide polymorphisms with warfarin dose adjustment in Saudi patients. *Drug Metab Pers Ther.* 2022 Apr 4;37(4):353-359. doi: 10.1515/dmpt-2022-0108. PMID: 36476275.
- [13] Lindley KJ, Limdi NA, Cavallari LH, Perera MA, Lenzini P, Johnson JA, Wu AHB, Ridker PM, King CR, Eby CS, Patel S, Shah SV, Beasley TM, Li J, Gage BF. Warfarin Dosing in Patients With CYP2C9*5 Variant Alleles. *Clin Pharmacol Ther.* 2022 Apr;111(4):950-955. doi: 10.1002/cpt.2549. Epub 2022 Feb 27. PMID: 35108398.
- [14] Cooper-DeHoff RM, Niemi M, Ramsey LB, Luzum JA, Tarkiainen EK, Straka RJ, Gong L, Tuteja S, Wilke RA, Wadelius M, Larson EA, Roden DM, Klein TE, Yee SW, Krauss RM, Turner RM, Palaniappan L, Gaedigk A, Giacomini KM, Caudle KE, Voora D. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. *Clin Pharmacol Ther.* 2022 May;111(5):1007-1021. doi: 10.1002/cpt.2557. Epub 2022 Mar 11. PMID: 35152405; PMCID: PMC9035072.
- [15] Nguyen HH, Nguyen CTT, Mai TNP, Huong PT. Associations between four polymorphisms of the SLCO1B1 and effectiveness of the statins: a meta-analysis. *Pharmacogenet Genomics.* 2023 Jun 1;33(4):65-78. doi: 10.1097/FPC.0000000000000490. Epub 2023 Mar 6. PMID: 37098851.
- [16] Pradana AD, Kristin E, Nugrahaningsih DAA, Nugroho AK, Pinzon RT. Influence of Solute Carrier Family 22 Member 1 (SLC22A1) Gene Polymorphism on Metformin Pharmacokinetics and HbA1c Levels: A Systematic Review. *Curr Diabetes Rev.* 2024;20(4):e070823219470. doi: 10.2174/1573399820666230807145202. PMID: 37550919.
- [17] Ortega-Ayala A, De Andrés F, Llerena A, Bartolo-Montiel CM, Molina-Guarneros JA. Impact of SLC22A1 variants rs622342 and rs72552763 on HbA1c and metformin plasmatic concentration levels in patients with type 2 diabetes mellitus. *Biomed Rep.* 2024 Jun 17;21(2):117. doi: 10.3892/br.2024.1806. PMID: 38938740; PMCID: PMC11209864.
- [18] Chen P, Cao Y, Guo Y, Xu Q, Wang X, Zhang L, Liu Z, Chen D, Chen S, Chen S. Association of SLC22A1 rs622342 and ATM rs11212617 polymorphisms with metformin efficacy in patients with type 2 diabetes. *Pharmacogenet Genomics.* 2022 Feb 1;32(2):67-71. doi: 10.1097/FPC.0000000000000454. PMID: 34545025.
- [19] Ghafoor MB, Yasmeen F, Khalid AW, Mustafa G, Khaliq S, Mohsin S. VKORC1 gene polymorphism (-1639G>A) in warfarin therapy patients of Pakistani population. *J Pak Med Assoc.* 2022 Mar;72(3):418-423. doi: 10.47391/JPMA.01042. PMID: 35320217.
- [20] Aldiban W, Altawil Y, Hussein S, Aljamali M, Youssef LA. Hyper-responsiveness to warfarin in a young patient with the VKORC1 -1639GA/CYP2C9*1*46 genotype: a case report. *Thromb J.* 2022 Oct 27;20(1):65. doi: 10.1186/s12959-022-00425-8. PMID: 36303140; PMCID: PMC9608913.